2018-06-06

[#DIV28SUPER] FW: [DIVTRIO] Call for Nominations: RxP Designation Committee

Esteemed Colleagues -

The APA is seeking nominations for two positions on the RxP Designation Committee.  Members of Division 28 are particularly well-suited to fill these important roles.  Please contact Kristyn Dempsey (email below) to inquire further or to self-nominate. 

Best regards,
Mark
President, Division 28

*********************
Mark Smith, PhD
Department of Psychology
Program in Neuroscience
Davidson College
Box 7037
Davidson, NC 28035-7037

phone: 704-894-2470
fax: 704-894-2512

From: APA Division Presidential trios communicating about divisional topics <DIVTRIO@LISTS.APA.ORG> on behalf of "Dempsey, Kristyn" <KDempsey@APA.ORG>
Reply-To: APA Division Presidential trios communicating about divisional topics <DIVTRIO@LISTS.APA.ORG>
Date: Monday, June 4, 2018 at 1:54 PM
To: "DIVTRIO@LISTS.APA.ORG" <DIVTRIO@LISTS.APA.ORG>
Subject: [DIVTRIO] Call for Nominations: RxP Designation Committee

Please consider distributing this message to your division listserv if it is of interest to your members:

 

The American Psychological Association (APA) Board of Education Affairs (BEA) and the Committee for the Advancement of Professional Practice (CAPP) are seeking nominations to fill two seats on the Designation Committee for Postdoctoral Education and Training Programs in Psychopharmacology for Prescriptive Authority (RxP Designation Committee). Please share with groups and individuals who have the relevant expertise and qualifications mentioned in the attached call for nominations. Completed nomination materials should be sent to Kristyn Dempsey, kdempsey@apa.org, no later than 5:00 p.m. EDT on Monday, August 6, 2018.

 

Thank you,

 

Kristyn Dempsey

Assistant Director, Professional Psychology Programs, Education Directorate

American Psychological Association

750 First Street NE, Washington, DC 20002

202-336-5775

 

Click on this link to unsubscribe from this list UNSUBSCRIBE

An email will automatically open with "Unsubscribe" in the subject area. Just Send the message, as is, to unsubscribe from this list..

2018-06-04

[#DIV28SUPER] Call for Papers: Special Issue on “Early Intervention Services for Serious Mental Illness”

NB "... Optimal ways to integrate pharmacology and psychosocial interventions for first episodes of serious mental illness ..."

Posted on behalf of Rose Sokol-Chang, Publisher of APA Journals

Call for Papers: Special Issue on "Early Intervention Services for Serious Mental Illness"

Deadline: September 1st, 2018

The editorial staff of Division 18's APA journal Psychological Services would like to invite you to submit articles for a special issue on Early Intervention Services for Serious Mental Illness that will be edited by Guest Editors Shirley M. Glynn, Ph. D. and Piper S. Meyer-Kalos, Ph.D., with Associate Editor, Femina P. Varghese, Ph.D.

It is becoming increasing recognized that early intervention in affective and non-affective psychosis can significantly improve the short-term trajectory of these illnesses. While there is a large body of scientific literature exploring the benefits of these interventions in countries with national health systems, research and implementation of these programs has lagged in the US. Recently, positive results of the National Institute of Mental Health (NIMH) Recovery After an Initial Schizophrenia Episode Early Treatment Program (RAISE-ETP) and Implementation and Evaluation Studies (RAISE-IES) have highlighted the value of Coordinated Specialty Care (CSC) in enhancing recovery from first episode non-affective psychosis in the US. Other investigators are exploring the utility of specialized early intervention programs for those experiencing a first episode of affective psychosis. In light of these results, the US Congress has established special funding to expand the availability of CSC programs throughout the country
Given the need for more literature on the development, use, and effectiveness of early intervention services for serious mental illnesses such as schizophrenia and bipolar illness in US public service settings and populations, this special issue is focused on publishing papers that cover early treatment services broadly, including reviews, empirical studies, innovative developments, program evaluations, and policy papers. Considering the nature of the journal, papers should be focused on the implementation of early intervention services for serious mental illness, including schizophrenia spectrum and bipolar disorders, in organized care settings such as community mental health settings, Indian Health Services, state and local prisons or jails, community health centers, university clinics, training hospitals, and local/state hospitals.

This special section will be devoted to all aspects of the implementation and evaluation of early intervention services for serious mental illness programs in US public service settings. Topics of interest include, but are not limited to:
Clinical outcome data from the implementation of these programs
Presentations of successful implementation of these programs with special populations (e.g. rural areas, low SES, ethnically or racially diverse, immigrants, etc.)
Comparative reviews of these programs as implemented throughout the US
Program evaluation papers demonstrating creative problem-solving of implementation challenges of these program (e.g. securing and sustaining funding, developing novel recruitment and retention strategies, managing staff turnover effectively)
Use of technology (e.g. telehealth, clinical apps) as a part of these programs
Enhancing the consumer role in the development, implementation, and staffing of these programs
Data on the unique benefits of participation in specific components of CSC (e.g. family interventions, individual therapy interventions, pharmacology, supported employment and education)
Data on participant outcomes of greater than two years duration
Greater specification of the participant recovery process
Optimal ways to integrate pharmacology and psychosocial interventions for first episodes of serious mental illness

In sum, we welcome manuscripts related to a variety of topics related to the early treatment of affective and/or non-affective psychosis in Public Service Settings, including empirical, conceptual, theoretical, and program evaluation papers focused on service provision. The deadline for receipt of papers for this special section is September 1st, 2018. Please follow the Instructions to Authors information located on the Psychological Services website at: http://www.apa.org/pubs/journals/ser. Manuscripts must be submitted electronically through the Manuscript Submission Web Portal as described on the journal's website, here: http://www.editorialmanager.com/svs/.

Please specify in your cover letter that the submission is intended for the special section on early treatment of affective and/or non-affective psychosis in Public Service Settings and address your submission cover letter to Dr. Femina P. Varghese, Dr. Shirley M. Glynn, and Dr. Piper S. Meyer-Kalos. All papers submitted will be initially screened by the editorial board and, if evaluated as appropriate for the journal, papers will then be sent out for blind peer review. For further questions related to this special section, please contact Dr. Varghese at fvarghese@uca.edu, Dr. Glynn at sglynn@ucla.edu, and Dr. Meyer-Kalos at psmeyer@umn.edu


Sent from my iPhone
_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org

[#DIV28SUPER] Experimental and Clinical Psychopharmacology


Dear Colleagues
I am writing to you in my role as the editor for APA's Experimental and Clinical Psychopharmacology. I have identified your division as one that may have an interest in the journal's content. The journal accepts brief communications (no more than 3000 words, excluding references; no more than 2 total figures or tables), case reports (no more than 2000 words; only 1 figure or table), brief reviews (no more than 5000 words, excluding references), original research reports (no word limit, but should typically be 4-8000 words, excluding references) and full reviews (no word limit).
With conference season upon us, I hope you will take the relevant presentations and posters you are preparing and turn them into manuscripts to submit to the journal.
Please feel free to contact me directly at william.stoops@uky.edu if you have questions about Experimental and Clinical Psychopharmacology.
Thank you,
Bill Stoops.



Journal Scope

Experimental and Clinical Psychopharmacology


 

Experimental and Clinical Psychopharmacology® publishes advances in translational and interdisciplinary research on psychopharmacology, broadly defined, and/or substance abuse.The scope of research in these areas continues to expand and to benefit from collaborations across a broad range of disciplines, including behavioral science, biochemistry, brain imaging, genetics, medicine, neuroendocrinology, neuroscience, and pharmacology.


The overall goal of Experimental and Clinical Psychopharmacology is to provide a forum for high-quality, innovative preclinical and clinical research that advances our understanding of the behavioral and biological determinants of the effects of centrally acting drugs.The journal publishes original reports and brief communications on the development and evaluation of pharmacotherapies for a range of mental health diagnoses, the influence of genetics and hormones on responses to psychoactive drugs, the pharmacological management of pain, and brain imaging studies of the neural correlates of psychoactive drug effects. Rigorous preclinical and human laboratory studies, as well as controlled clinical trials of novel interventions, relevant to psychopharmacology and/or substance abuse, are particularly encouraged. The journal recommends that all submissions consider relevant biological variables (e.g., age, animal strain, sex) that may influence outcomes in study design and statistical analyses.


When appropriate (e.g., to provide initial clinical documentation of an emerging issue or topic in psychopharmacology and/or substance abuse), the journal will publish case reports. Case reports are expected to be thoughtful and thorough with attention paid to underlying etiology, behavioral, clinical, and laboratory findings. Any hypotheses should be supported by data and extant literature. The journal will also include integrative reviews, both full and brief, of advances in research on psychopharmacology and/or substance abuse. Full reviews should provide a broad perspective on a particular area of research or trace the development of critical concepts and experimental approaches. Brief reviews should provide a scholarly perspective on a circumscribed topic or a novel area that has a relatively small number of relevant research studies to consider. It is recommended that authors contact the editor prior to review preparation regarding suitability for the journal.


Each year, the journal will recognize individuals who are recipients of awards from APA Division 28 (Psychopharmacology and Substance Abuse). Awardees will be invited to submit a full or brief review paper based on their award-winning research contributions.


Disclaimer: APA and the editors of Experimental and Clinical Psychopharmacology® assume no responsibility for statements and opinions advanced by the authors of its articles.





               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684


Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
Component Lead
Research Methods
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2018-05-29

[#DIV28SUPER] Editorial Fellowship Available for Experimental and Clinical Psychopharmacology

Experimental and Clinical Psychopharmacology announces an opening for an Editorial Fellow position, beginning January 1, 2019. The position is open to qualified candidates who hold the rank of Assistant Professor (or equivalent) and will last one year. During this time, the selected Fellow will work closely with the journal's Editor, Dr. William W. Stoops, to develop editorial and publishing proficiency, enrich scientific knowledge and bolster written communication skills. It is anticipated that the Fellow will manage approximately one manuscript per month. This process will include identifying reviewers, making an editorial decision based on review and shepherding the manuscript through to publication if accepted, all with guidance from Dr. Stoops. The successful candidate will also be expected to participate in monthly meetings with Dr. Stoops to ensure goals are met and problems are identified and addressed. The majority of these meetings will be phone conferences, although in-person meetings at scientific conferences are also possible. Upon successful completion of the fellowship, the Editorial Fellow will become a member of the journal's editorial board. All applications should include the following: 1) an interest statement, 2) a curriculum vitae and 3) three recommendation letters. Application materials are due to Dr. Stoops (william.stoops@uky.edu) on September 1, 2018 at 5 PM Eastern time and should be submitted as a single pdf file. Applications will be reviewed by members of the Experimental and Clinical Psychopharmacology editorial board for strength of the interest statement, research and publishing experience, manuscript review experience and enthusiasm of the recommendation letters. The top candidate will be notified of her/his selection by December 1, 2018. Address any questions to Dr. Stoops at william.stoops@uky.edu.



               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684


Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
Component Lead
Research Methods
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2018-05-15

[#DIV28SUPER] Special Issue Call for Papers

Call for Papers: Experimental and Clinical Psychopharmacology

 

Special Issue for April 2019 on:

Therapeutic and Abuse-Related Effects of Cannabis and Cannabinoids

 

This special issue will provide an overview of current research on cannabis and cannabinoids with an emphasis on issues related to their legalization for medical and recreational use.  We encourage submission of review articles and original research reports in this area, including the following topics: therapeutic efficacy of cannabis and cannabinoids across different disease conditions; etiology of cannabinoid use disorders; consequences of cannabinoid exposure during pregnancy, adolescence, and adulthood; development of forensic testing for detecting acute cannabis intoxication;  influence of route of cannabinoid administration on therapeutic effects and abuse liability;  variations in THC content across cannabis strains and cannabinoid-enriched products, and implications for use; current federal restrictions on cannabis research; prevalence of synthetic cannabinoids, issues with their regulation, mechanisms of action and consequences of their use; and changes in public perceptions of perceived harm of medicinal and recreational cannabis and cannabinoid use.

 

Researchers in this area may submit review articles or primary research reports to Experimental and Clinical Psychopharmacology to be considered for inclusion in this special issue. Manuscripts should be submitted as usual through the APA Online Submission Portal (http://pha.edmgr.com/), and the cover letter should indicate that the authors wish the manuscript to be considered for publication in the special issue on Therapeutic and Abuse-Related Effects of Cannabis and Cannabinoids.  All submissions will undergo our normal peer review. Manuscripts received no later than October 1, 2018 will be considered for inclusion in the special issue. We strongly encourage individuals to contact the guest editors in advance with their ideas and a draft the title and abstract.

 

Questions or inquiries about the special issue can be directed to the Guest Editors of the issue, Ashley Acheson, PhD, awacheson@uams.edu, or William Fantegrossi, wefantegrossi@uams.edu, or the Editor, William Stoops, PhD at william.stoops@uky.edu.



               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684


Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
Component Lead
Research Methods
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2018-05-14

[#DIV28SUPER] Job opening

Se below...
From: Brian Borsari, PhD <brian.borsari.sfva.ucsf@gmail.com>
Sent: Monday, May 14, 2018 9:59:25 AM
To: Adam Matthew Leventhal
Subject: Can you post to Div 28 list serve and to any interested colleagues?
 

The San Francisco VA Health Care System Mental Health Service and Department of Psychiatry, University of California, San Francisco invite applications for an 8/8th behavioral health research psychologist. We are seeking applicants who are Principal Investigator (PI), Co-PI, or Co-Investigator on externally funded research projects, and the candidate will be expected to maintain an active portfolio of externally funded clinical research at a high level of investigative independence involving complex research programs and/or multi-site research trials or collaborations. Candidate will also perform direct clinical care as part of Primary Care Mental Health Integration team, with an emphasis on behavioral health in the primary care setting (e.g., mood and anxiety management secondary to health conditions, chronic pain, weight loss, diabetes management, tobacco use cessation, sleep hygiene). Programmatic support for the position also includes start-up funding and designated office and research space within the Mental Health Service at the SFVA. The candidate will be proposed for appointment as an affiliate-paid Professor in the In Residence series at a rank and series commensurate with experience. Candidates must be a US citizen and have a PhD/PsyD in clinical/counseling psychology from an American Psychological Association (APA) approved program and completion of an APA-approved internship. Position is posted for current VA employees at https://www.usajobs.gov/GetJob/ViewDetails/499473300 and for non-VA employees athttps://www.usajobs.gov/GetJob/ViewDetails/499473400  

For more information, contact Brian Borsari, PhD at 415-221-4810 x26078 or brian.borsari@ucsf.edu or brian.borsari@va.gov. Applications due by 6/1/2018.

 


On 9 April 2018 at 16:43, Adam Leventhal <adam.leventhal@usc.edu> wrote:
Dear Colleagues:

The American Psychological Association (APA) Division on Psychopharmacology and Substance Abuse (Division 28) is seeking nominations for new Fellows. As described by APA, "Fellow status is an honor bestowed upon APA members who have shown evidence of unusual and outstanding contributions or performance in the field of psychology. Fellow status requires that a person's work has had a national impact on the field of psychology beyond a local, state, or regional level. A high level of competence or steady and continuing contributions are not sufficient to warrant fellow status. National impact must be demonstrated."

In Division 28 a successful nominee will typically be 10+ years post-doctorate, have a track record of substantial external funding and publication productivity, and can document the national impact of their research on the psychopharmacology and substance abuse fields.

If you would like to nominate a colleague for consideration for Fellow status, please send their CV and contact information to the address below. You may also nominate somebody who is already an APA Fellow (with relevance to our Division), but who is not yet a Fellow of Division 28. Self-nominations are also welcomed.

Contact Information for Fellow Nominations:

Adam Leventhal, Ph.D.
adam.leventhal@usc.edu
APA Division 28 Fellows Chair

Don't hestitate to contact me if you had any further questions.

Best,

Adam
--
Adam Leventhal, Ph.D.
Director, USC Health, Emotion, & Addiction Laboratory
Professor of Preventive Medicine and Psychology
USC Norris Comprehensive Cancer Center
Keck School of Medicine
University of Southern California
2250 Alcazar St., CSC 271
Los Angeles, CA 90033
Phone: 323-442-8222
Fax: 323-442-2359
heal.usc.edu

_______________________________________________
Apadiv50-forum mailing list
Apadiv50-forum@mailman.yale.edu
https://mailman.yale.edu/mailman/listinfo/apadiv50-forum




--
******************************************************************************************
Brian Borsari, Ph.D.

Health Behavior Coordinator/Clinical Psychologist

Building 8, Room 108

San Francisco VA Medical Center (116B)

4150 Clement Street

San Francisco, CA 94121

Phone: (415) 221-4810 x26078

FAX: (415) 750-6987


Professor in Residence

Department of Psychiatry

UCSF Weill Institute for Neurosciences

University of California, San Francisco

http://ncire.org/research/researcher_directory/Brian-Borsari-PhD/

http://profiles.ucsf.edu/brian.borsari


Adjunct Professor of Behavioral and Social Sciences
Center for Alcohol and Addiction Studies
Brown School of Public Health


******************************************************************************************






2018-05-08

[#DIV28SUPER] 14th Annual Mechanisms of Behavior Change Satellite Session June 16 (free one day meeting)

Registration for the 14th Annual Mechanisms of Behavior Change satellite session on June 16th in San Diego is still open at https://casaa.unm.edu/mechanismsofchange.

 

The theme for this year is “Transbehavioral Mechanisms and Processes of Change” and features seven leaders in the field of addiction, science of behavior change, and quantitative methods. This free one-day meeting also includes informal networking opportunities, and an update on funding initiatives from the National Institute on Alcohol Abuse and Alcoholism and the Science of Behavior Change program (NIH Common Fund).

 

At our website you will find a registration form for the upcoming session, which features exciting talks on the science of behavior change by Drs. Lisa Marsch, Kathleen Carroll, Allison Harvey, Jun Ma, and Joshua Smythe, as well as a keynote methods address by Dr. Kevin Grimm.  We would also appreciate if you forward this email to colleagues and trainees who might be interested in attending. 

 

To register and find more information about the day please go to our website at:
https://casaa.unm.edu/mechanismsofchange

 

 

Thank you for your time and interest,

Katie Witkiewitz and Mitch Karno

MOBC Satellite Planning Committee

 

Katie Witkiewitz, PhD

Professor

Department of Psychology

Center on Alcoholism, Substance Abuse, and Addictions

MSC03-2220

University of New Mexico

Albuquerque NM 87131

Office phone: 505-277-5953

Vmail: 505-925-2334

Fax: 505-277-1394

http://casaa.unm.edu/kwitkiewitz.html